Adoptive t-cell therapy for b-cell malignancies

Michael Hudecek, Larry D. Anderson, Tetsuya Nishida, Stanley R. Riddell

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT. T cells that are capable of recognizing antigens expressed on malignant B cells may be recruited from the endogenous repertoire or engineered to express tumor-targeting receptors. Critical insights into the qualities of T cells that enable their persistence and function in vivo have been derived, and obstacles to effective T-cell-mediated tumor eradication are being elucidated. These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies.

Original languageEnglish (US)
Pages (from-to)517-532
Number of pages16
JournalExpert Review of Hematology
Volume2
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Cell- and Tissue-Based Therapy
T-Lymphocytes
Cell Transplantation
Neoplasms
B-Lymphocytes
Adoptive Transfer
Antigens

Keywords

  • Adoptive T-cell therapy
  • Allogeneic hematopoietic cell transplantation
  • Central memory T cell
  • Chimeric antigen receptor
  • Graft-versus-host disease
  • Graft-versus-tumor effect
  • Immunoglobulin idiotype
  • Minor histocompatibility antigen
  • T-cell receptor

ASJC Scopus subject areas

  • Hematology

Cite this

Adoptive t-cell therapy for b-cell malignancies. / Hudecek, Michael; Anderson, Larry D.; Nishida, Tetsuya; Riddell, Stanley R.

In: Expert Review of Hematology, Vol. 2, No. 5, 2009, p. 517-532.

Research output: Contribution to journalArticle

Hudecek, Michael ; Anderson, Larry D. ; Nishida, Tetsuya ; Riddell, Stanley R. / Adoptive t-cell therapy for b-cell malignancies. In: Expert Review of Hematology. 2009 ; Vol. 2, No. 5. pp. 517-532.
@article{7951c32fa1774c4181b2260b1808cc9f,
title = "Adoptive t-cell therapy for b-cell malignancies",
abstract = "The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT. T cells that are capable of recognizing antigens expressed on malignant B cells may be recruited from the endogenous repertoire or engineered to express tumor-targeting receptors. Critical insights into the qualities of T cells that enable their persistence and function in vivo have been derived, and obstacles to effective T-cell-mediated tumor eradication are being elucidated. These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies.",
keywords = "Adoptive T-cell therapy, Allogeneic hematopoietic cell transplantation, Central memory T cell, Chimeric antigen receptor, Graft-versus-host disease, Graft-versus-tumor effect, Immunoglobulin idiotype, Minor histocompatibility antigen, T-cell receptor",
author = "Michael Hudecek and Anderson, {Larry D.} and Tetsuya Nishida and Riddell, {Stanley R.}",
year = "2009",
doi = "10.1586/ehm.09.47",
language = "English (US)",
volume = "2",
pages = "517--532",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Adoptive t-cell therapy for b-cell malignancies

AU - Hudecek, Michael

AU - Anderson, Larry D.

AU - Nishida, Tetsuya

AU - Riddell, Stanley R.

PY - 2009

Y1 - 2009

N2 - The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT. T cells that are capable of recognizing antigens expressed on malignant B cells may be recruited from the endogenous repertoire or engineered to express tumor-targeting receptors. Critical insights into the qualities of T cells that enable their persistence and function in vivo have been derived, and obstacles to effective T-cell-mediated tumor eradication are being elucidated. These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies.

AB - The success of allogeneic hematopoietic cell transplantation (HCT) for B-cell malignancies is evidence that these tumors can be eliminated by T lymphocytes. This has encouraged the development of specific adoptive T-cell therapy, both for augmenting the anti-tumor effect of HCT and for patients not undergoing HCT. T cells that are capable of recognizing antigens expressed on malignant B cells may be recruited from the endogenous repertoire or engineered to express tumor-targeting receptors. Critical insights into the qualities of T cells that enable their persistence and function in vivo have been derived, and obstacles to effective T-cell-mediated tumor eradication are being elucidated. These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies.

KW - Adoptive T-cell therapy

KW - Allogeneic hematopoietic cell transplantation

KW - Central memory T cell

KW - Chimeric antigen receptor

KW - Graft-versus-host disease

KW - Graft-versus-tumor effect

KW - Immunoglobulin idiotype

KW - Minor histocompatibility antigen

KW - T-cell receptor

UR - http://www.scopus.com/inward/record.url?scp=77953383957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953383957&partnerID=8YFLogxK

U2 - 10.1586/ehm.09.47

DO - 10.1586/ehm.09.47

M3 - Article

C2 - 21083018

AN - SCOPUS:77953383957

VL - 2

SP - 517

EP - 532

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 5

ER -